{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:04Z","timestamp":1753891864068,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The PD-1 inhibitor sintilimab has been approved for the treatment of various malignancies. Here, we reported a rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer and liver metastasis to raise awareness of this serious adverse event. A 64-year-old man presented with the onset of gastric cancer and liver metastasis and received two cycles of sintilimab plus nab-paclitaxel. The patient experienced fever, thrombocytopenia, and rash during the first-cycle treatment, followed by bilateral ptosis, dysphagia, slurred speech, and myalgia during the second-cycle treatment. Elevated muscle enzymes, electromyography, and positive myositis antibodies confirmed the diagnosis of dermatomyositis. He was treated with high-dose corticosteroids and immunoglobulin, resulting in symptom improvement. This case widens the spectrum of immune-related toxicity associated with sintilimab, as well as highlights the need for early recognition and management of these events in patients receiving ICIs.<\/jats:p>","DOI":"10.3389\/fonc.2025.1517391","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:10:40Z","timestamp":1744776640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Peipei","family":"Mou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"biomark Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (Icis); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101896","article-title":"Uncommon adverse events of immune checkpoint inhibitors in small cell lung cancer: A systematic review of case reports","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.3390\/cancers14092276","article-title":"Association of rare immune-related adverse events to survival in advanced cancer patients treated with immune checkpoint inhibitors: A real-world single-center cohort study","volume":"14","author":"Kuusisalo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2188719","article-title":"Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations","volume":"12","author":"Park","year":"2023","journal-title":"Oncoimmunology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma","volume":"104","author":"Berger","year":"2018","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2020.1811189","article-title":"Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung","volume":"34","author":"Wiggins","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa832","article-title":"Anti-tif1gamma antibody-positive dermatomyositis in a 15-year-old boy with epstein-barr virus-related nasopharyngeal cancer receiving nivolumab","volume":"60","author":"Asano","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103375","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","volume":"22","author":"Guerra","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6917-20","article-title":"Atezolizumab-associated dermatomyositis in advanced small-cell lung carcinoma","volume":"60","author":"Yamaguchi","year":"2021","journal-title":"Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2770","article-title":"A case of drug-associated dermatomyositis following ipilimumab therapy","volume":"26","author":"Yamaguchi","year":"2016","journal-title":"Eur J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.895187","article-title":"Efficacy and safety evaluation of sintilimab for cancer treatment: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Ye","year":"2022","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.21037\/apm-20-2449","article-title":"Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: A case report of sintilimab-induced myocarditis and a review of the literature","volume":"10","author":"Bi","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B19","article-title":"Electrochemiluminescence method","author":"Premnath","year":"2023","journal-title":"StatPearls"},{"key":"B20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (Sitc) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts","volume":"36","author":"Bogdanov","year":"2018","journal-title":"Clin Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5070\/D3268049887","article-title":"Dermatomyositis associated with nivolumab therapy for melanoma: A case report and review of the literature","volume":"26","author":"Messer","year":"2020","journal-title":"Dermatol Online J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00396-6","article-title":"Toripalimab-induced dermatomyositis in a patient with metastatic melanoma","volume":"10","author":"Lin","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac Allergy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_1306_20","article-title":"Immunotherapy-intensified paraneoplastic dermatomyositis","volume":"88","author":"Estenaga","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: A minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.55563\/clinexprheumatol\/knb47b","article-title":"Anti-tif1-gamma antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Clin Exp Rheumatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1517391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:10:42Z","timestamp":1744776642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1517391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1517391"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1517391","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1517391"}}